Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Effect of a Comprehensive Package Based on Multimarker Blood-based Point-of-care Testing on Antibiotic Prescribing for Acute Respiratory Tract Infections at Village Clinics in China

11 november 2026 bijgewerkt door: Xiaoxv Yin, PhD, Huazhong University of Science and Technology

This is a pragmatic, parallel-group, superiority, cluster-randomised controlled trial designed to evaluate the effect of a comprehensive intervention package, based on multimarker blood-based POCT on antibiotic prescribing for ARIs in village clinics in China.

Studie Overzicht

Toestand

Nog niet aan het werven

Interventie / Behandeling

Gedetailleerde beschrijving

This is a pragmatic, parallel-group, superiority, cluster-randomised controlled trial designed to evaluate the effect of a comprehensive intervention package, based on multimarker blood-based POCT on antibiotic prescribing for ARIs in village clinics in China. We will conduct the trial over six months in 80 village clinics across 10 townships in Xiantao and Jingmen, Hubei Province (with 5 townships in Xiantao and 5 in Jingmen). Village clinics will be randomly assigned in a 1:1 ratio to either the intervention or control group, stratified by city and township. A comprehensive intervention package based on multimarker blood-based POCT will be implemented in 40 village clinics within the intervention group. In addition to equipping these clinics with POCT devices, we will provide systematic guidance through a combination of centralised training sessions and the distribution of training manuals. The training will focus on the standardised operation of POCT and clinical pathways to guide antibiotic prescriptions for the treatment of ARIs based on test results. We will provide patient education through leaflets, primarily aimed at helping rural patients understand how multimarker blood-based POCT can aid in their diagnosis and treatment, thereby improving patient acceptance. The control group will undergo diagnosis and treatment in accordance with routine care procedures, without any intervention.

Studietype

Ingrijpend

Inschrijving (Geschat)

70000

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

    • Hubei
      • Jingmen, Hubei, China, 448000
      • Xiantao, Hubei, China, 433000

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Kind
  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Eligibility criteria for clusters. Village clinics will be eligible if they have not previously participated in a POCT-guided antibiotic prescribing programme, record more than 2,000 outpatient visits annually, manage an average of at least 10 patients with ARIs per week, and have licensed prescribers. Eligibility will be verified using prescription records from the preceding year obtained from the information management departments of the local health authorities.

Eligibility criteria for participants. The target population comprises patients of all ages who either (1) have been diagnosed by village doctors with an ARI, including upper or lower respiratory tract infections; or (2) present with at least one acute respiratory symptom or sign, such as cough, sore throat, rhinitis (nasal congestion, sneezing, or rhinorrhoea), wheezing, or abnormal findings on auscultation. Patients diagnosed with non-respiratory conditions and those whom village doctors consider require referral to a higher-level healthcare facility based on their clinical presentation will be excluded.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Geen tussenkomst: Control group

The control group will not have any intervention, as the control (usual care)

Experimenteel: Intervention group

All village clinics in the intervention group will be provided with a combined POCT system for CBC parameters, CRP, and SAA, together with the required reagent kits, for use in patients with ARIs.

All village clinics in the intervention group will be provided with a combined POCT system for CBC parameters, CRP, and SAA, together with the required reagent kits, for use in patients with ARIs.

Each intervention clinic will receive a concise, easy-to-follow decision flowchart summarising the prespecified thresholds for selected CBC parameters, CRP, and SAA.

Following randomisation, all village doctors in the intervention group will receive standardised centralised training.

The research team will also provide each village clinic in the intervention group with a guidance manual on appropriate antibiotic use for ARIs supported by combined CBC, CRP, and SAA POCT.

Plain-language, non-technical information leaflets will be distributed at all village clinics in the intervention group.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
The primary outcome will be a binary indicator of whether at least one antibiotic is prescribed by the village doctor during an eligible index consultation for an ARI.
Tijdsspanne: The 6-month intervention

An index consultation is defined as an ARI-related consultation by a patient who has not had any recorded ARI consultations at the same village clinic in the preceding 14 days. This measure aims to capture the overall effect of the POCT-supported multicomponent intervention on antibiotic prescribing decisions for ARIs. Since most ARIs are viral and self-limiting, a lower prescribing proportion-provided that patient recovery and safety are not compromised-would indicate more selective use of antibiotics by village doctors. This endpoint is particularly suitable for research in village clinics in China because prescriptions are now routinely recorded electronically rather than solely on paper. These digital records enable standardised data extraction and auditing, thereby supporting the completeness and traceability of outcome ascertainment.

The 6-month intervention

Secundaire uitkomstmaten

Uitkomstmaat
Tijdsspanne
The proportion of eligible index consultations in which two or more antibiotics are prescribed
Tijdsspanne: The 6-month intervention
The 6-month intervention
The proportion in which at least one antibiotic is administered intravenously
Tijdsspanne: The 6-month intervention
The 6-month intervention
The proportion in which at least one traditional Chinese medicine is prescribed
Tijdsspanne: The 6-month intervention
The 6-month intervention
The medication cost per eligible index consultation
Tijdsspanne: The 6-month intervention
The 6-month intervention
The total cost per eligible index consultation
Tijdsspanne: The 6-month intervention
The 6-month intervention

Andere uitkomstmaten

Uitkomstmaat
Tijdsspanne
The proportion of patients who initiate any additional antibiotic during the 14 days following an eligible index consultation for an ARI will be assessed in a randomly selected subsample
Tijdsspanne: The 6-month intervention
The 6-month intervention
The principal safety outcome will be the proportion of patients admitted to any hospital within the corresponding study city for an ARI or sepsis within 30 days after the index consultation.
Tijdsspanne: The 6-month intervention
The 6-month intervention
In the randomly selected patient subsample, we will also assess time to recovery from ARI symptoms through the 14-day telephone follow-up.
Tijdsspanne: From the index consultation to the end of treatment at 2 weeks
From the index consultation to the end of treatment at 2 weeks

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

15 december 2026

Primaire voltooiing (Geschat)

15 juni 2027

Studie voltooiing (Geschat)

15 juli 2027

Studieregistratiedata

Eerst ingediend

11 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

11 november 2026

Eerst geplaatst (Werkelijk)

17 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

17 november 2026

Laatste update ingediend die voldeed aan QC-criteria

11 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • HuazhongU20261111

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren